All Stories

Roche, AbbVie say trial of Venclexta in patients with myelodysplastic syndromes falls short

Roche and AbbVie have once again come up short in their attempt to gain an additional indication for their blockbuster blood cancer treatment Venclexta.

Jun 16, 2025 - 21:40
 0
Roche, AbbVie say trial of Venclexta in patients with myelodysplastic syndromes falls short
Roche and AbbVie have once again come up short in their attempt to gain an additional indication for their blockbuster blood cancer treatment Venclexta.
Read More

Tags:

Previous Article

Veranova, Enzene plot new biologic manufacturing expansions on East Coast

Next Article

Lockheed says new upgrade package for F-35 is ready

Related Posts

Diabetes patients who use GLP-1s may have a higher risk of serious eye disease: study

Diabetes patients who use GLP-1s may have a higher risk...

Jun 6, 2025  0

Pharmas to face higher drug rebates in UK despite government's tweak to proposal

Pharmas to face higher drug rebates in UK despite gover...

Jun 11, 2025  0

Sanofi opens doors to $130M 'flagship' US office facility in New Jersey

Sanofi opens doors to $130M 'flagship' US office facili...

May 22, 2025  0